Galecto Reports $3.1 Million Net Loss in Q3 2025, Seeks Additional Funding

Galecto, Inc. reported a net loss of $3.1 million for the third quarter of 2025, a decrease from the $3.9 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company’s net loss was $9.1 million, down from $14.7 million in the prior year. The reduction in losses is attributed to a significant decrease in operating expenses, which totaled $3.2 million for the quarter, compared to $3.8 million in the previous year. This decline was primarily driven by a 36.7% reduction in general and administrative expenses, which fell to $1.7 million, while research and development expenses increased by 29.6% to $1.4 million due to higher costs associated with chemistry, manufacturing, and clinical trial activities.

In terms of financial position, Galecto's cash and cash equivalents decreased to $7.6 million as of September 30, 2025, down from $14.2 million at the end of 2024. The company’s total current assets also declined to $9.8 million, while current liabilities increased to $2.6 million from $1.2 million. The accumulated deficit reached $286.6 million, reflecting ongoing operational losses since the company's inception. The company has indicated that its existing cash reserves may not be sufficient to fund operations for the next twelve months, raising concerns about its ability to continue as a going concern without securing additional funding.

Strategically, Galecto has undergone significant organizational changes, including a restructuring plan initiated in September 2023, which involved a workforce reduction and a shift in focus towards the development of its oncology and liver disease product candidates, GB3226 and GB1211. The company entered into an Asset Purchase Agreement with Bridge Medicines in October 2024, acquiring the global rights to the BRM-1420 program, now known as GB3226, which targets acute myeloid leukemia (AML). This strategic pivot aims to maximize shareholder value and streamline the company’s research and development efforts.

Operationally, Galecto is currently focused on advancing GB3226 through preclinical development, with plans to submit an investigational new drug application (IND) to the FDA in early 2026. The company has received positive feedback from the FDA regarding its pre-IND submission, which supports its timeline for initiating a Phase 1 clinical trial. Additionally, Galecto is continuing its GALLANT-1 trial for GB1211, which has shown promising results in combination with existing therapies for melanoma and head and neck cancers.

Looking ahead, Galecto anticipates that it will require substantial additional capital to finance its operations and clinical development programs. The company is exploring various funding options, including equity or convertible debt financing, but acknowledges the uncertainty surrounding the availability of such funding. If adequate financing is not secured, Galecto may need to reevaluate its operational plans, potentially leading to further reductions in spending or the scaling back of development programs.